Detalles de la búsqueda
1.
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Int J Clin Oncol;
2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38758397
2.
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Invest New Drugs;
42(1): 136-144, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38300341
3.
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).
Transl Lung Cancer Res;
12(8): 1702-1716, 2023 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691865
4.
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol;
41(34): 5242-5246, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37656928
5.
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Transl Lung Cancer Res;
12(6): 1167-1184, 2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37425411
6.
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Cancer Sci;
114(9): 3698-3707, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37434391
7.
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Qual Life Res;
32(9): 2629-2637, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37126140
8.
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.
Cancer Med;
12(13): 14327-14336, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37211905
9.
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Future Oncol;
19(2): 123-135, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36877099
10.
Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications.
Crit Rev Oncol Hematol;
184: 103966, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36925092
11.
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Int J Clin Oncol;
28(5): 724-725, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648711
12.
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Int J Clin Oncol;
27(12): 1839-1840, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36243793
13.
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
JTO Clin Res Rep;
3(10): 100406, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36247019
14.
Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.
Front Oncol;
12: 965741, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36313664
15.
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Int J Clin Oncol;
27(12): 1828-1838, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036294
16.
Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study.
Thorac Cancer;
13(17): 2499-2506, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869676
17.
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
JTO Clin Res Rep;
3(6): 100332, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35663414
18.
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).
Int J Clin Oncol;
27(9): 1404-1412, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723758
19.
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.
Thorac Cancer;
13(15): 2192-2200, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768976
20.
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Lung Cancer;
169: 67-76, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35660971